Written answers

Tuesday, 8 November 2016

Department of Health

Medicinal Products Data

Photo of Mick WallaceMick Wallace (Wexford, Independent)
Link to this: Individually | In context | Oireachtas source

395. To ask the Minister for Health if he will provide a full list of all drugs removed from the GMS medical card scheme and a list of those drugs whose availability has been restricted under the scheme since 1 January 2015; if the drug Macushield has been removed or restricted; the estimated number of persons here suffering from age related macular degeneration, AMD; the number of persons, accurate or estimated, here over 65 years of age who suffer from AMD; if a value figure is available for a year's supply of Macushield for the average AMD sufferer; if there is funding available to medical card holders for Macushield; if Macushield has been removed or restricted, the reason it was removed or restricted; and if he will make a statement on the matter. [33739/16]

Photo of Simon HarrisSimon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The HSE has advised that Macushield products have never been made available to all persons with medical card eligibility; however, Macushield and similar products were historically available to medical card holders in many areas under Discretionary Hardship Arrangements.

In developing a national framework for the administration of Discretionary Hardship Arrangements, the HSE's Medicines Management Programme (MMP) was asked to review the available therapeutic evidence for supporting reimbursement of Macushield and similar products. The MMP report supported the view of the National Centre for Pharmacoeconomics that the evidence for dietary carotenoids for the prevention of age-related macular degeneration (AMD) is inconclusive, and the MMP therefore does not recommend that products containing these preparations be reimbursed under any community drug scheme.

In light of the MMP's published report, the HSE decided to cease reimbursement support for these dietary supplement products. The MMP report is available at:

www.

As the other issues raised by the Deputy are operational and service matters, they have been referred to the HSE for reply to the Deputy.

Comments

No comments

Log in or join to post a public comment.